Comment Comment by AvocadoPanic The 'risk' here is often carried by publicly funded research. ~6.2 billion for glpThe private 'investment' comes in manufacturing, scale and marketing.Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years. parent AvocadoPanic 10 months ago
The private 'investment' comes in manufacturing, scale and marketing.
Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years.